Total amount: € 0,00
Official Journal of the Italian Society of Social Psychiatry
Indexed/Abstracted in: EMBASE, e-psyche, PsycINFO, Scopus
Online ISSN 1827-1731
Pieraccini F., Lombardelli A., Calossi S., Castrogiovanni P.
Olanzapine is traditionally regarded as a first choice treatment in psychotic disorders. Moreover, a growing amount fo evidence supports its use in mood disorders as well, both in acute manic or mixed phase and as a maintenance long term therapeutic agent. The use of olanzapine as antimanic agent is broadly accepted and its use in acute mania is approved by the Food and Drug Administration and by the Pharmaceutical Commission (Commissione Unica per il Farmaco) in Italy. A review is made of data that recently have suggested the effectiveness of olanzapine in the treatment of acute mania of mixed states, of rapid cyclings and in the long-term prophylactic therapy of bipolar disorder. According to the literature, the lower risk of depressive switch and a greater effectiveness in preventing manic phases are underlined. Many controlled and open label studies agree about the tollerability and safety of olanzapine, a safe and easy to handle drug. The 2 cases reported have been personally observed and show the efficacy of olanzapine in the treatment of bipolar disorder's.